TRACON Pharmaceuticals, Inc. (TCON)
Stock Price:
$4.80 USD
0.12 (2.56%)
Updated Oct 29, 2020 12:56 PM EDT - Market open
Key Info
| Market Cap |
63.28M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-17.61M |
| Shares Out |
13.18M |
| EPS (ttm) |
-3.98 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 29, 2020 |
| Last Price |
$4.80 |
| Previous Close |
$4.68 |
| Change ($) |
0.12 |
| Change (%) |
2.56% |
| Day's Open |
4.64 |
| Day's Range |
4.57 - 4.84 |
| Day's Volume |
68,532 |
| 52-Week Range |
0.95 - 6.37 |
More Stats
| Market Cap |
63.28M |
| Enterprise Value |
53.33M |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
13.18M |
| Float |
12.46M |
| EPS (basic) |
-4.35 |
| EPS (diluted) |
-3.98 |
| FCF / Share |
-3.13 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
343,476 |
| Short Ratio |
0.22 |
| Short % of Float |
2.76% |
| Beta |
1.11 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
19.84 |
| Revenue |
n/a |
| Operating Income |
-17.09M |
| Net Income |
-17.61M |
| Free Cash Flow |
-19.97M |
| Net Cash |
9.95M |
| Net Cash / Share |
0.75 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-49.00% |
| ROE |
-295.37% |
| ROIC |
441.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (3)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$5.33*
(11.04% upside)
Low
3.00
Current: $4.80
High
7.00
Target: 5.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | 3.00 | 8.76 | 3.45 | 7.90 | 3.60 | - | - |
| Revenue Growth | - | -65.73% | 153.84% | -56.36% | 119.68% | - | - | - |
| Gross Profit | - | 3.00 | 8.76 | 3.45 | 7.90 | 3.60 | - | - |
| Operating Income | -22.30 | -34.74 | -18.21 | -25.98 | -23.47 | -6.18 | -7.56 | -5.23 |
| Net Income | -22.67 | -34.96 | -19.10 | -27.01 | -24.41 | -6.81 | -7.71 | -4.93 |
| Shares Outstanding | 3.03 | 2.69 | 1.68 | 1.27 | 1.11 | 0.16 | 0.16 | 0.16 |
| Earnings Per Share | -7.47 | -12.97 | -11.37 | -21.30 | -22.00 | -44.00 | -49.30 | -31.90 |
| Operating Cash Flow | -23.65 | -30.78 | -13.24 | -27.15 | -19.16 | 1.76 | -6.67 | -5.43 |
| Capital Expenditures | - | - | -0.04 | - | -0.13 | -0.07 | -0.01 | -0.01 |
| Free Cash Flow | -23.65 | -30.78 | -13.28 | -27.15 | -19.29 | 1.69 | -6.68 | -5.44 |
| Cash & Equivalents | 16.41 | 39.10 | 34.47 | 44.41 | 52.16 | 35.00 | 2.28 | - |
| Total Debt | 5.34 | 6.43 | 7.44 | 8.31 | 8.84 | 8.93 | 2.44 | - |
| Net Cash / Debt | 11.07 | 32.68 | 27.03 | 36.10 | 43.31 | 26.07 | -0.17 | - |
| Assets | 18.12 | 40.65 | 36.13 | 45.73 | 53.52 | 38.17 | 2.42 | - |
| Liabilities | 15.42 | 19.21 | 19.14 | 17.39 | 22.54 | 70.35 | 27.76 | - |
| Book Value | 2.70 | 21.44 | 16.99 | 28.34 | 30.98 | -32.17 | -25.34 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
TRACON Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
19 |
| CEO |
Charles P. Theuer |
Stock Information
| Ticker Symbol |
TCON |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: TCON |
| IPO Date |
January 30, 2015 |
Description
TRACON Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD. The company also develops TRC102, a small molecule that is in Phase II clinical trial for mesothelioma, Phase I clinical trial for solid tumors and lung cancer, and Phase I/II clinical trial for solid tumors and lymphomas; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trial for the treatment prostate cancer. In addition, it is developing TJ004309, a novel humanized antibody against CD73 that is in Phase I clinical trial to treat patients with solid tumors through a strategic collaboration and clinical trial agreement with I-Mab Biopharma. The company has license agreements with Ambrx, Inc.; Santen Pharmaceutical Co. Ltd.; Roswell Park Cancer Institute and Health Research Inc.; Case Western Cancer Center; and Lonza Sales AG, as well as a cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.